Antineoplastic Drugs in Elderly Patients

Recruiting now

Conditions studied: Cancer

In brief

The purpose is to study the population pharmacokinetics, effectiveness and safety of antineoplastic drugs (Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib, Imatinib, Lapatinib, etc) in elderly patients and recommend optimized dosage regimens.

Key facts

Study ID

NCT05467189

Run by

Shandong University

People needed

500

Starts

2021-01-01

Expected to finish

2028-06-30

Last updated by the study team

2022-07-20

Who can join

Age: 65 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must meet all of the following inclusion criteria to be enrolled in the study:
• Age ≥65 years old;
• Diagnosed with cancer;
• Using antineoplastic drugs for treatment.

You may not qualify if…

• Subjects with any of the following criteria will not be enrolled in this study:
• Patients who are expected to die within 48 hours;
• Patients with allergy to antineoplastic drugs;
• Patients receiving other investigational drugs;
• Other factors that the researcher considers unsuitable for inclusion.

Where it is running

• Shandong Provincial Qianfoshan Hospital — Jinan, Shandong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.